EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Continuing Glucagon-Like Peptide-1 Receptor Agonists Into the First Trimester of Pregnancy and Pregnancy Outcomes

Jeremy P Brown iD, Krista F Huybrechts iD, Loreen Straub iD, Elisabetta Patorno iD, Ellen W Seely iD, Brian T Bateman, Sonia Hernández-Díaz iD

Annals of Internal Medicine · 2026

DOI: 10.7326/annals-25-04820 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Annals of Internal Medicine, 2026. Verfasst von Jeremy P Brown und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, and Faculty of Life Sciences & Medicine, King's College…. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Pregnancy Outcome, Hypoglycemic Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Glucagon-like peptide-1 receptor agonist (GLP-1RA) use has increased among women of reproductive age, but limited data exist on safety in pregnancy. OBJECTIVE: To estimate the risk for nonlive birth, abnormal fetal growth, and major congenital malformation (MCM) with GLP-1RA dispensing in early pregnancy. DESIGN: In an observational cohort of pregnant women aged 16 to 55 years with a GLP-1RA dispensation in the 90 days before the last menstrual period (LMP), a target trial with 2 treatment strategies was emulated: continuation of dispensing into the first trimester (≥1 further dispensation), or noncontinuation. SETTING: Merative MarketScan U.S. insurance claims data (2011 to 2024). PARTICIPANTS: 3572 pregnancies (41.1% [n = 1467] among women with type 2 diabetes). MEASUREMENTS: Risk for nonlive birth was estimated using a weighted Kaplan-Meier estimator. Among live-birth pregnancies linked to infants, the weighted prevalence of MCM, small for gestational age (SGA), and large for gestational age (LGA) was estimated. RESULTS: The weighted risk for nonlive birth was 29.7% with continuation and 27.1% with noncontinuation (adjusted risk ratio, 1.09 [95% CI, 0.98 to 1.23]). Among 2529 live-birth pregnancies, 1443 (57.1%) received at least 1 GLP-1RA dispensation after LMP and 1499 (829 continuers) were linked to an infant. Weighted prevalence ratios for continuation versus noncontinuation were 1.29 (CI, 0.82 to 2.06) for SGA, 1.08 (CI, 0.84 to 1.40) for LGA, and 1.21 (CI, 0.83 to 1.82) for MCM. LIMITATION: Potential residual confounding by prior glycemic control. CONCLUSION: Risks for nonlive birth, SGA, LGA, and MCM were not definitively higher with continuation of GLP-1RAs into early pregnancy. However, estimates for MCM and SGA were imprecise and were compatible with both no increased risk and clinically relevant differences in risk. PRIMARY FUNDING SOURCE: National Institutes of Health.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsPregnancy OutcomeHypoglycemic AgentsDiabetes Mellitus, Type 2Pregnancy in DiabeticsHumansFemalePregnancyAdultAdolescentYoung AdultPregnancy Trimester, FirstMiddle AgedAbnormalities, Drug-InducedInfant, NewbornInfant, Large for Gestational AgeUnited StatesInfant, Small for Gestational Age

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic Agents

Autor:innen und Institutionen

  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, and Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom (J.P.B.).
  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (K.F.H., L.S., E.P.).
  • Endocrinology, Diabetes and Hypertension Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (E.W.S.).
  • Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, California (B.T.B.).
  • Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts (S.H.-D.).

ORCID-Profile: Jeremy P Brown, Krista F Huybrechts, Loreen Straub, Elisabetta Patorno, Ellen W Seely, Sonia Hernández-Díaz

Förderung

  • NICHD NIH HHS

Zitieren

APA

Brown, J. P., Huybrechts, K. F., Straub, L., Patorno, E., Seely, E. W., Bateman, B. T., & Hernández-Díaz, S. (2026). Continuing Glucagon-Like Peptide-1 Receptor Agonists Into the First Trimester of Pregnancy and Pregnancy Outcomes. Annals of Internal Medicine. https://doi.org/10.7326/annals-25-04820

Vancouver

Brown JP, Huybrechts KF, Straub L, Patorno E, Seely EW, Bateman BT, et al. Continuing Glucagon-Like Peptide-1 Receptor Agonists Into the First Trimester of Pregnancy and Pregnancy Outcomes. Annals of Internal Medicine. 2026. doi:10.7326/annals-25-04820

BibTeX
@article{Brown2026,
  author = {Brown, Jeremy P and Huybrechts, Krista F and Straub, Loreen and Patorno, Elisabetta and Seely, Ellen W and Bateman, Brian T and Hernández-Díaz, Sonia},
  title = {Continuing Glucagon-Like Peptide-1 Receptor Agonists Into the First Trimester of Pregnancy and Pregnancy Outcomes},
  journal = {Annals of Internal Medicine},
  year = {2026},
  doi = {10.7326/annals-25-04820}
}
Kostenlos starten →